GLucobay M - Evaluation Of Safety and Effectiveness in Type 2 Diabetes Not Well Controlled on Monotherapy in Real Life Practice - GLORY

Bayer Zydus Pharma0 个研究点目标入组 10,000 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•Patient will be enrolled after the decision to administer acarbose/metformin fixed dose combination for type-2 diabetes management has been made by the attending physician on the basis of best clinical practice and patient needs.
•Willing to give informed consent for participating in this study

•Patients receiving anti-diabetic medication other than acarbose, or metformin monotherapy at the time of enrollment in the study will be excluded. However, during observation period, any additional anti-diabetics medication administered by the attending physician will be allowed & recorded in case record form.
•Patient receiving acarbose/metformin fixed dose combination during 3-months prior to enrollment.
•Exclusion criteria should be read in conjunction with local product information

发起方

Bayer Zydus Pharma